Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 9, Issue 6, 2014, Pages 659-670

  Yabe, Daisuke ^a,b   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

albiglutide; DPP 4 inhibitor; dulaglutide; exenatide; exenatide LAR; GLP 1 receptor agonist; incretin; liraglutide; lixisenatide; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALPHA GLUCOSIDASE INHIBITOR; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING DRUG; METFORMIN; MICROSPHERE; POLYMER; SHORT ACTING DRUG; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ADD ON THERAPY; ANTIDIABETIC ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ETHNIC DIFFERENCE; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SEX DIFFERENCE; SUSTAINED RELEASE FORMULATION; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 84911466764     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.2014.949672     Document Type: Review

References (120)

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58(4): 773-95
2. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010;1(1-2):8-23
3. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17(6): 819-37
4. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95(1):215-21
5. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281(1):E155-61
6. Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;25(6): 781-92
7. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88(6): 2719-25
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87(4):1409-39
9. Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96(3):737-45
10. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-31
11. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53(3): 654-62
12. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36(11-12):867-76
13. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010;16(Suppl 7):S187-94
14. Ahrén B, Gautier JF, Berria R, et al. Pronounced reduction of post-prandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014. [Epub ahead of print]
15. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85(11):4053-9
16. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes-Relationship to postprandial glycemia. Regul Pept 2013; 185(1):8
17. Meier JJ, Yabe D, Wang E, et al. Efficacy of lixisenatide in patients with different levels of beta cell function as assessed by Cpeptide/glucose ratio. Diabetologia 2013; 56(Suppl 1):S1-S566; Abstract 896
18. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683):39-47
19. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53(5):1187-94
20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8(12): 728-42
21. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88(7):3082-9
22. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting betacells. J Biol Chem 1993;268(26):19650-5
23. FDA. Amylin Pharmaceuticals Inc. Byetta prescribing information. 2009
24. Bristol-Myers Squibb and AstraZeneca EEIG. Byetta: Summary of product characteristics. EMA. 2012
25. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5): 1092-100
26. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5):1083-91
27. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35
28. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559-69
29. Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307(2): 490-6
30. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164(2-3):58-64
31. Distiller RA, Ruus P; on behalf of the ACT6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes 2008;58(Suppl 1):A154-5
32. Ratner RE, Rosenstock J, Boka G. Dosedependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, doubleblind, placebo-controlled trial. Diabet Med 2010;27(9):1024-32
33. Ahrén B, Leguizamo DA, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36(9):2543-50
34. Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 2014;31:176-84
35. Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013; 15(11):1000-7
36. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, openlabel, active-controlled study (GetGoal-X). Diabetes Care 2013;36(10):2945-51
37. Bolli GB, Owens DR. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes Obes Metab 2014;16(7): 588-601
38. Ahren B. Equal improvement in glycemia with lixisenatide given before breakfast or the main meal of the day. J Diabetes Complications 2014. [Epub ahead of print]
39. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50(1):65-74
40. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376(9739): 431-9
41. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
42. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new longacting GLP-1 derivative, in healthy men. Diabetologia 2002;45(2):195-202
43. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009; 373(9662):473-81
44. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78
45. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90
46. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met +TZD). Diabetes Care 2009;32(7):1224-30
47. Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013;15(3): 213-23
48. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012;14(8):762-7
49. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381(9861):117-24
50. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a longacting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93(12):4810-17
51. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2(4): 289-97
52. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87(3):1239-46
53. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303(14):1410-18
54. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14(9):810-20
55. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epacdependent manner. Diabetes 2011;60(1): 218-26
56. Yabe D, Seino S. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or Foe J Diabetes Investig 2014. [Epub ahead of print]
57. Wang Y, Li L, Yang M, et al. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. Diabetes Obes Metab 2011;13(11): 972-81
58. Mulligan CM, Harper R, Harding J, et al. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther 2013;4(1): 147-51
59. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37(8):2159-67
60. Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med 2013; 125(3):47-57
61. Rosenstock J, Forst T, Aronson R, et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: getgoal-duo 1 study. Abstract #62-OR. Presented at: American Diabetes Association, 2012
62. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagonlike peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014. [Epub ahead of print]
63. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3(1):e001986
64. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49(11): 1353-62
65. Darpo B, Zhou M, Matthews J, et al. Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study. Diabetes Ther 2014;5(1):141-53
66. Linnebjerg H, Seger M, Kothare PA, et al. A thorough QT study to evaluate the effects of singledose exenatide 10 mug on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther 2011;49(10):594-604
67. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362(9):774-7
68. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8(3):237-40
69. Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2014;16(1):38-47
70. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44(5): 904-9
71. Singh S, Chang HY, Richards TM, et al. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a populationbased matched case-control study. JAMA Intern Med 2013;173(7):534-9
72. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33(11):2349-54
73. Monami M, Dicembrini I, Nardini C, et al. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014;103(2):269-75
74. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370(9):794-7
75. Bjerre KL, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-86
76. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96(3):853-60
77. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1): 150-6
78. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36(Suppl 2):S245-52
79. Kawata T, Kanamori A, Kubota A, et al. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients? J Clin Med Res 2014;6(2):138-44
80. Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagonlike peptide-1 analogues between Asians and non-Asians: a systematic review and metaanalysis. Diabetes Obes Metab 2014. [Epub ahead of print]
81. Seino Y, Takami A, Boka G, et al. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab 2014;16(8):739-47
82. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004;66(Suppl 1): S37-43
83. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig 2012;3(1):70-9
84. Yabe D, Kuroe A, Watanabe K, et al. Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls. J Diabetes Investig 2010;1(1-2):56-9
85. Meier JJ, Vilsboll T, Donsmark M, et al. Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass. Diabetologia 2011;54(Suppl 1):1-542
86. Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced Î 2-cell function. J Diabetes Invest 2001;4(6): 585-94
87. Anichini R, Cosimi S, Di CA, et al. Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes 2013;6:123-9
88. Yabe D, Seino Y. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol 2013;13(6):946-53
89. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85(3):579-89
90. Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4(2):108-30
91. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154(2):103-12
92. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;35(7):1446-54
93. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36(9): 2489-96
94. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
95. Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a metaanalysis. Exp Diabetes Res 2012;2012:672658
96. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101(3):515-20
97. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33(2):187-215
98. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-5
99. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012;98(5):408-13
100. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5(2): 288-95
101. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33(12):1491-9
102. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a metaanalysis of clinical trials. Diabetes Obes Metab 2013;15(8):737-49
103. Fonseca VA, Devries JH, Henry RR, et al. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014;28(3): 399-405
104. Irace C, De LS, Shehaj E, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013;10(1):72-7
105. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013;19(5): 567-75
106. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans. Diabetologia 2006;49(3):452-8
107. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010;212(1):217-22
108. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-ofconcept study. Diabetes Care 2010;33(7): 1509-15
109. Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2012;41(1):119-44
110. Nayak UA, Govindan J, Baskar V, et al. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103(9): 687-94
111. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011;13(11):1020-7
112. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36(9): 2489-96
113. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-Week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36(9):2497-503
114. Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract 2012;66(12):1147-57
115. Gross JL, Kramer CK, Leitao CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154(10):672-9
116. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16(7):636-44
117. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2013;16(1):30-7
118. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375(9733):2234-43
119. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96(5): 1301-10
120. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care 2014;37(8):2168-76